Krystal Biotech, Inc.
KRYS
Clasificación en acciones
#2124
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Precio por acción
$326.41
Última sincronización: 2026-10-20
Capitalización bursátil
$9.66B
Cambio (1 día)
1.92%
Cambio (1 año)
71.09%
País
US
Comercio Krystal Biotech, Inc. (KRYS)
Categoría
Healthcare
Ingresos de Krystal Biotech, Inc. (KRYS)
Ingresos en Jun 2026 TTM: $440.48M
Según los últimos informes financieros de Krystal Biotech, Inc., los ingresos actuales de la empresa (TTM) son $440.48M. En 2023, la empresa obtuvo unos ingresos de $50.70M un aumento con respecto a los ingresos del año 2022, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Krystal Biotech, Inc. desde 2016 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $440.48M | 51.62% |
| 2024 | $290.52M | 473.02% |
| 2023 | $50.70M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | $1.03M | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 2,766.01% |
US
|
|
| $2.23B | 405.81% |
US
|
|
| $15.74B | 3,474.32% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 1,266.97% |
NL
|
